Table 1.

Comparison of systemic therapy for advanced (unresectable stage III or stage IV) melanoma

Treatment	RR (%)	PFS (med), months	OS (med/2-years)
Single-agent BRAFi	50	6–8	18.7 months/~ 40%
Combo BRAFi and MEKi	65–70	9–12	15 months/~ 50%
Ipilimumab	10	2–3	12 months/~ 30% (20% 5 year survival)
Anti-PD-1 mAb (nivolumab or pembrolizumab)	25–45	~ 6	18–24 months/~ 50%
Combo ipilimumab and nivolumab	~ 60	11–12	Unk./~ 64%